Cong Ma, Pangbo Yang, Rumeng Du, Simin Yang, Zhiwei Xu
{"title":"Molecular Mechanisms and Clinical Applications of SGLT2 Inhibitors in Cardiovascular Diseases.","authors":"Cong Ma, Pangbo Yang, Rumeng Du, Simin Yang, Zhiwei Xu","doi":"10.1007/s12265-026-10794-4","DOIUrl":null,"url":null,"abstract":"<p><p>Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a vital therapy that bridges glycemic control and cardiovascular protection, fundamentally changing the way the Cardiovascular-Kidney-Metabolic (CKM) syndrome is managed. This review summarises the current evidence on the molecular mechanisms of SGLT2 inhibitors, ranging from haemodynamic regulation to metabolic reprogramming, and their clinical applications in various cardiovascular diseases. We critically discuss the pharmacological characteristics of different agents, as well as the debate surrounding glucose-dependent versus glucose-independent mechanisms. Furthermore, we summarise current guideline recommendations to provide clinicians with a reference for incorporating SGLT2 inhibitors into the treatment of heart failure and other cardiovascular conditions.</p>","PeriodicalId":15224,"journal":{"name":"Journal of Cardiovascular Translational Research","volume":"19 1","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2026-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Translational Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12265-026-10794-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a vital therapy that bridges glycemic control and cardiovascular protection, fundamentally changing the way the Cardiovascular-Kidney-Metabolic (CKM) syndrome is managed. This review summarises the current evidence on the molecular mechanisms of SGLT2 inhibitors, ranging from haemodynamic regulation to metabolic reprogramming, and their clinical applications in various cardiovascular diseases. We critically discuss the pharmacological characteristics of different agents, as well as the debate surrounding glucose-dependent versus glucose-independent mechanisms. Furthermore, we summarise current guideline recommendations to provide clinicians with a reference for incorporating SGLT2 inhibitors into the treatment of heart failure and other cardiovascular conditions.
期刊介绍：
Journal of Cardiovascular Translational Research (JCTR) is a premier journal in cardiovascular translational research.
JCTR is the journal of choice for authors seeking the broadest audience for emerging technologies, therapies and diagnostics, pre-clinical research, and first-in-man clinical trials.
JCTR''s intent is to provide a forum for critical evaluation of the novel cardiovascular science, to showcase important and clinically relevant aspects of the new research, as well as to discuss the impediments that may need to be overcome during the translation to patient care.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
